Cognitive impairment

Please choose the clinical evaluation:

• 123I-Ioflupane / DaTSCAN™ is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:
  To help differentiate probable dementia with Lewy bodies from Alzheimer’s disease.
  DaTSCAN is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia
• 18FDOPA / DOPACIS™ is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:
  To help differentiate probable dementia with Lewy bodies from Alzheimer’s disease.
  DOPACIS™ is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia
• Detection and differential diagnosis of suspected dementia disorders
• Persistent or progressive unexplained mild cognitive impairment.
  The core clinical criteria for possible AD are satisfied, but there is an unclear clinical presentation-either an atypical clinical course or an etiologically mixed presentation.
  Patients with progressive dementia and atypically early age of onset (usually defined as 65 years or less in age).